Amterdam Institute for Global health & Development aighd
1
Ana Cecília Gomes Rosa Luiz, Bruna Silveira Caixeta, Milena Ferreira Cruvinel et al.
1
Anaya-Covarrubias, J.Y.
1
and L.Lockerd Maragakis
1
and C. Hoffmann
1
and C. Wonodi
1
and K. Geffert
1
Argote P., Barhan E., Zukerman Daly S. et al.
1
Armocida, B.
1
Arrieta, A.
1
ARUP Laboratories
1
Asean Briefing
1
Australian Government Department of Health
1
ÄZQ
1
B. Mason Meier
1
B.S. Kamps
1
BC Centre for Disease Control
1
Beauftragte der Bundesregierung für Migration, Flüchtlinge und Integration
1
Berger, S.
1
Bhopal,S., and M. Nielsen
1
Bigoni, A.
1
BioNTech
1
BMC
1
BMC Health Services
1
Bouley, T. A.
1
Bracho C., Martinez C. et al.
1
Brazilian Journal of Health Review
1
Breathrough Action - For social and behavior change
1
British Medical Association BMA
1
British Medical Journal
1
British Society for Immunology
1
Buliva E., Elnossery S., Okwarah P. et al.
1
Bundesministerium für Migration und Flüchtlinge BAMF
1
C.
1
C. Clift
1
C. Ferreira-Borges
1
C. Victora and M. Chowdury.
1
Camp, R. and C. Hoffmann
1
Care and ONU Femmes
1
Care, ONUu Femmes et al.
1
Carolina L.A. Barbieri, C. Carvalho de Souza Amorim Matos
1
Carrillo-Larco
1
Castillo C., Villalobos Dintrans P. et al
1
Castro, A.
1
Catholic Agency for Overseas Development CAFOD
1
CDA Collaborative Learning Projects
1
Center for Operational Analysis and Research COAR
1
Center for Public Interest Communications, University of Florida
1
Centers for Disease Control and Prevention
1
Cerda A. A., Garcia L. Y.
1
Chairmen of the Committee on Doctrine and the Committee on Pro-Life Activities
1
Children for Health
1
Chimimba, F.
1
Clinical Drug Information, Inc. and its affiliates and
1
Coalition for Epidemic Preparedness Innovations (CEPI)
1
Coision Nacional de Seguridad en Vacunas
1
Collective Service RCCE
1
Compass
1
Conlon C., T. McDonnell, M. Barrett, et al.
1
Conseil International des Infirmières
1
Conseil international des Infirmières (CII)
1
Corinne Grainger
1
Corona Tracker
1
Corvalan, C.
1
Couto,M.T.
1
COVID-19 Mental Disorders Collaborators
1
Cristina Aldaz, Francisco Perez
1
D. B. Evans
1
das Neves Martins Pires P.H. , Macaringue C. , Abdirazak A. et al.
1
Department of Health, Republic of South Africa
1
Desogus, A.
1
Deutsche Gesellschaft für Internationale Zusammenarbeit GmbH (GIZ)
1
Dheda, K.
1
DHS Program Demographic and Health Surveys
1
Dirección de Control de Enfermedades Inmunoprevenibles
1
Dorcas Aid International
1
Doubova SV, Leslie HH, Kruk ME, et al.
1
Dr. J. Breda
1
Dr. P. Amoth
1
Dr. S. K. Kibias
1
Dressler D. D., MD, MSc Director OF
1
Drug Safety
1
Dzabala, N. et al.
1
E. Levy Yeyati
1
E. Ross
1
E. Villalobos Prats, A. Sena et al.
1
E. Webb, M. Mckee et al.
1
Eba, B.
1
Education Santé
1
Elsevier Ltd
1
Emanuel, E.J., et al.
1
Engelman, D. et al.
1
EQUINET
1
et al
1
Ethiopian Food and Drug Authority
1
Ethiopian Food, Medicine and Healthcare Administration and Control Authority
1
EUAA European Union
1
EuroHealth Observer
1
European & Developing Countries Clinical Trials Partnership EDCTTP
1
European AIDS Clinical Society (EACS)
1
European Asylum Support Office
1
European Centers for Disease Control and Prevention ECDC
1
European Centre for disease prevention and Control
1
European Centre for Disease Prevention and Control ECDC
1
European Centre for Disease Prevention and Control (ECDC)
1
European Centre for Disease Prevention and Control ECDC, IOM
1
European Commission's Directorate-General for European Civil Protection and Humanitarian Aid Operations ECHO
1
European Observatory on Health Systems and Policies Eurostation
1
European specialist nurse organisation (ESN)
1
F. Bozzani et al.
1
F. Filippini
1
F. O. Fasina, Fasanmi O.G., Makonnen Y. J., et al.
1
F. Zerbinato Bispo Velasco, de Oliveira Pedroza, G.G. et al.
1
Federal Ministry of Health, Uganda
1
Florida International University
1
Food and Agriculture Organization of the United Nations (FAO)
1
Frase N. S.
1
GAVI Alliance
1
Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO
1
Gavi, the Vaccine Alliance
1
GBD 2019 Human Resources for Health Collaborators
1
GEF
1
German Agency for Quality in Medicine (ÄZQ)
1
Gideon
1
Global Alliance for Vaccines and Immunisation (Gavi)
1
Global Coalition for Circulatory Health
1
Global Financing Facility (GFF)
1
Global Fund
1
Global Institute for Asthma
1
Global Polio Eradication Initiative (GPEI
1
GMDAC, University of Potsdam
1
GOARN
1
Gomes Machado, F.C. et al.
1
Goodman, T.
1
Government of Burundi World Health Organization
1
Government of Malawi
1
Government of the Democratic Republic of the Congo
1
Government of the Republic of Moldova United Nations in Moldova
1
Government of the Republic of Namibia
1
Government of Uganda
1
Greinacher, A., et al.
1
Guzman-Vilca, W. C.
1
H. Adler, Gould, S.
1
Haarmann, E.
1
Haider, N.
1
Haldane, V., De Foo, C., Abdalla, S.M. et al.
1
Harding-Zentrum für Risikokompetenz
1
Hategeka C, Carter SE, Chenge FM, et al.
1
Health Care without Harm
1
Health Cluster, Nutrition Cluster, OCHA
1
Health Cluster, WHO
1
Health Sector Syria
1
Healthcare Triage
1
Heinrich-Böll Stiftung, European Union EU
1
Heliyon
1
Hine, P.
1
Hoffmann, C.
1
Holt, E.
1
Holy See Press Office
1
Honein MA, Christie A, Rose DA, et al.
1
Hopkins, D.
1
Hussein Ahmed
1
ICG
1
IFRC - International Federation of Red Cross
1
IHME Institut for Health Metrics and Evaluation
1
ILO
1
iMMAP
1
Immunization Action Coalition
1
Imperial College COVID-19 Response Team
1
Infection Prevention and Control UHL, WHO Headquarters
1
Institut de Médecine Tropicale, Université de Bordeau
1
Institute for research in international assistance
1
Inter-agency Task Force on Financing for Development
1
International Commission of Jurists
1
International Crisis Group
1
International Federation of Red Cross and Red Crescent Societies IFR
1
International Institute for Environment and Developmend (IIED)
1
International Organization for Migration (IOM)
1
International Rescue Committee
1
International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health
1
IOM Displacement Tracking Matrix - South Sudan
1
IQ-COVID Bremen
1
J. Bueno de Mesquita
1
J. Ferdosy
1
J. Kates, A. Wexler, et al.
1
J. Tjaden
1
Janković, M.
1
Jara A., Undurraga E. A. et al
1
John Hopkins Bloomberg School
1
John Hopkins University
1
Jurkovič, I.
1
Jusot, V.
1
Kalla, I.S.
1
Kelen, G.D.
1
KFF
1
Kim, A.
1
Knoll, M.D.
1
Knowledge Translation Unit
1
Kohler, S.
1
Kompetenznetz Public Health zu COVID-19
1
Kuehn, B.M.
1
Kulkarni, S.
1
Kurowski, C.
1
L. Aparecida de Souza Teles and E.G. da Silva Andrade
1
la DiCEI del Ministerio de Salud de la Nación en conjunto con la Comisión Nacional de Seguridad en Vacunas (CoNaSeVa)
1
Lalloo, U.G.
1
Lancet Oncology Commission
1
Leon-Velarde, F.
1
Lewis, C. Jr., Akinyi, M., DeWitte, S. et al.
1
Limaya, R.J.
1
Logothetis, E.
1
Logunov, D.Y, et al.
1
Louka, C.
1
M. A. Babu
1
M. Dara
1
M. M. Ahmmed
1
Machalaba
1
Machalaba, C.
1
Magalhães, C.R.
1
Malawi Human Rights Commission
1
MAMI, Irish Aid, Eleanor Crook Foundation
1
Martinez Viciana, C.
1
Mauder, S., K. Geffert
1
MEDBOX- The Aid libary
1
Medical Aid Films
1
Medicines and Healthcare products Regulatory Agency (MHRA) UK
1
Migration Policy Institute
1
Ministerio da Saude do Brasil
1
Ministerio de Salud Chile
1
Ministerio de Salud El Salvador
1
Ministerio de Salud Pública del Ecuador
1
Ministerio de Salud y Proteccion Social Bogota, Colombia
1
Ministerio de Salud, Colombia
1
Ministerio de Salud, Bogota, Colombia
1
Ministero della Salute
1
Ministère de la Santé, DR Congo
1
Ministério da Saúde Brasil
1
Ministério da Saúde, Brasil
1
Ministry of Health
1
Ministry of Health & Family Welfare ,India
1
Ministry of Health & Family Welfare Government of India
1
Ministry of Health & Family Welfare, Goverment of India
1
Ministry of Health and Family Welfare, India
1
Ministry of Health Ghana
1
Ministry of Health Rwanda, The DHS Program, et al.
1
Ministry of Health Uganda
1
Ministry of Health, Liberia, World Health Organization (WHO), and Centers for Disease Control and Prevention (CDC)
1
Ministry of Health, South Africa
1
Misereor, Brot für die Welt, Global Policy Forum GPF
1
Mixed Migration Centre
1
Morbidity and Mortality Weekly Report MMWR
1
Mortimer, K.
1
Msomi, N.
1
Multidisciplinary Collaborative Group for the Scientific Monitoring of COVID-19 (GCMSC)
1
N.Paul, T. Bärnighausen, P. Geldsetzer
1
National Academies of Sciences, Engineering, and Medicine
1
National Centre for Disease Control
1
National Department of Health (NDoH) South Africa
1
National Department of Health South Africa
1
National Department of Health South-Africa
1
National Libary of Medicine
1
NDoH South Africa
1
Neil M Ferguson, Daniel Laydon, Gemma Nedjati-Gilani, Natsuko Imai, Kylie Ainslie, Marc Baguelin, Sangeeta Bhatia, Adhiratha Boonyasiri, Zulma Cucunubá, Gina Cuomo-Dannenburg, Amy Dighe, Ilaria Dorigatti, Han Fu, Katy Gaythorpe, Will Green, Arran Hamlet, Wes Hinsley, Lucy C Okell, Sabine van Elsland, Hayley Thompson, Robert Verity, Erik Volz, Haowei Wang, Yuanrong Wang, Patrick GT Walker, Caroline Walters, Peter Winskill, Charles Whittaker, Christl A Donnelly, Steven Riley, Azra C Ghani.
COVID-19 Vaccines: 1 Safety Surveillance 2 Manual
While there is no indication that pregnant women have an increased susceptibility to infection with SARS-CoV-2, there is evidence that pregnancy may increase the risk of severe illness and mortality from COVID-19 disease in comparison with non-pregn...ant women of reproductive age. As seen with non-pregnant women, a high proportion of pregnant women have asymptomatic SARS-CoV-2 infection and severe disease is associated with recognized medical (e.g., high body-mass index (BMI), diabetes, pre-existing pulmonary or cardiac conditions) and social (e.g., social deprivation, ethnicity) risk factors. Pregnant women with symptomatic COVID-19 appear to have an increased risk of intensive care unit admission, mechanical ventilation and death in comparison with non-pregnant women of reproductive age, although the absolute risks remain low. COVID-19 may increase the risk of preterm birth, compared with pregnant women without COVID-19, although the evidence is inconclusive.more
La evidencia disponible a nivel internacional sobre el uso de un segundo refuerzo muestra una mayor duración de la respuesta inmune y una disminución de la internación y la mortalidad por COVID 19 en la población de adultos mayores y huéspedes inmunocomprometidos. Por otra parte, el personal de... salud se beneficiaría considerando el mayor riesgo de exposición y la caída de la respuesta inmune con el tiempo. En base a lo señalado previamente se recomienda incorporar y
priorizar un segundo refuerzo al esquema de vacunación contra la COVID-19 del:
- Personal de salud independientemente de la edad
- Personas de 50 años o mayores
- Personas de 12 años o más con inmunocompromiso
A la vez, se progresará de manera escalonada y simultánea con la vacunación de segundo refuerzo del:
- Personal estratégico
- Personas de 18 a 49 años con factores de riesgo
Continuando en la estrategia de segundo refuerzo todas las personas a partir de los 18 años. Las personas gestantes con indicación de segundo refuerzo, se recomienda vacunas de plataforma de ARNm (Pfizer-BioNTech o Moderna)more
Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se hab...a evaluado la eficacia).Entre los participantes sin evidencia de infección previa por SARS-CoV-2, hubo 3 casos de COVID-19 entre los 1.305 receptores de vacuna a partir de los 7 días de la segunda dosis y 16 entre los 663 receptores de placebo.more
Este informe presenta los resultados obtenidos de la evaluación de la efectividad de las vacunas contra la COVID-19 en Chile utilizando la red de vigilancia centinela de infecciones respiratorias agudas graves (IRAG). Los resultados que se presentan en este informe provienen de los datos proporcion...ados por esta red para el periodo de enero a diciembre de 2021.more
En Paraguay, la vacunación contra COVID-19 inició el 22 de febrero de 2021. Se han autorizado un total de siete vacunas: Bharat-Covaxin, Moderna, Pfizer-BioNTech, AstraZeneca, Sinopharm, Sputnik V- Gamaleya y CoronaVac-Sinovac. Los grupos prioritarios de vacunación están definidos según el Plan... Nacional de Vacunación contra COVID-19 en Paraguaymore
This research report offers community perceptions of COVID-19 from migrants, refugees, host communities and indigenous populations in nine countries in the Americas: Argentina, Brazil, Bolivia, Colombia, Guatemala, Nicaragua, Jamaica, Panama and Trinidad and Tobago.
It reveals the myriad impacts ...that COVID-19 has had, and continues to have, on vulnerable and hard-to-reach populations. And it offers hands-on recommendations around the impact and usefulness of health information; trust, awareness and access to vaccines; and the socio-economic impact of the pandemic.more
To its credit, Chile has implemented a highly successful vaccine program and taken a number of other important public health measures to improve the well-being of its inhabitants. Nevertheless, these measures have proved insufficient to curb the spread of the virus and ensure full compliance wit...h Chile’s obligations to respect, protect and
fulfil the right to health. It is in this context that this report examines the human rights impacts of the pandemic and the responses of the Chilean authorities.more
Learn about the composition and delivery mechanism for the new classes of COVID-19 vaccines based on adenovirus from Johnson & Johnson and AstraZeneca with Dr. Jonathan Genzen, COO of ARUP Laboratories and an Associate Professor at the University of Utah School of Medicine.
It estimates that there have been 228,000 additional deaths of children under five in these six countries [Afghanistan, Nepal, Bangladesh, India, Pakistan and Sri Lanka] due to crucial services, ranging from nutrition benefits to immunisation, being halted.
It says the number of children being tr...eated for severe malnutrition fell by more than 80% in Bangladesh and Nepal, and immunisation among children dropped by 35% and 65% in India and Pakistan respectively...
It also estimates that there have been some 3.5 million additional unwanted pregnancies, including 400,000 among teenagers, due to poor or no access to contraception...
The interruption to health services also affected those suffering from other diseases - the report predicts an additional 5,943 deaths across the region among adolescents who couldn't get treated for tuberculosis, malaria, typhoid and HIV/Aids.more
Summary of the main report: Direct and indirect effects of COVID-19 pandemic and response in South Asia .
It uses a series of exercises based on actual observed changes in services and intervention coverage to model impacts on mortality, hospitalizations, and ICU admissions due to COVID-19. It a...lso models the impact of nationwide stay-at-home orders to curb the spread of COVID-19 on maternal and child mortality, educational attainment of children, and the region’s economy. The study focuses on South Asia’s six most populous countries: Afghanistan, Bangladesh, Nepal, India, Pakistan and Sri Lanka and makes the case for interventions and strategies to minimise these indirect consequences.more
O Protocolo de Vigilância Epidemiológica e Sanitária de Eventos Adversos Pós-Vacinação (EAPV), é o documento de referência nacional para a vigilância das vacinas COVID-19. Além disso, complementará, com os demais protocolos definidos pelo Ministério da Saúde, as ações empreendidas par...a o enfretamento da pandemia de Covid-19 no país.
O desenvolvimento e a operacionalização do Protocolo obrigam à definição clara de uma estrutura de liderança, coordenação e harmonização, bem como à identificação das entidades com responsabilidades no planejamento, na execução e na avaliação das atividades estabelecidas nas três esferas de gestão do Sistem Unico de Saude. Para tanto, este Protocolo preconiza o fortalecimento da integração dos atores do SUS, bem como de segmentos da sociedade brasileira, envolvidos direta ou indiretamente com a minimização de riscos e monitoramento de EAPV.
Este documento apresenta orientações gerais estruturantes e procedimentos para o funcionamento eficiente do sistema de farmacovigilância/vigilância de eventos adversos pós-vacinação (VEAPV) nas diferentes esferas de gestão do Sistema Unico de Saude, especificamente quanto as questões de segurança e queixas técnicas de vacinas.more
– з вакциною на білковій основі
(Nuvaxovid® виробництва Novavax)
Станом на: 15 лютого 2022 р. (даний інформаційний лист постійно оновлюється)
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Cor...ona Virus Disease 2019) (Grundimmunisierung )
– mit proteinbasiertem Impfstoff –
(Nuvaxovid® von Novavax)
Stand: 15. Februar 2022 (dieser Aufklärungsbogen wird laufend aktualisiert)
(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer und Spikevax® von Moderna)more